GLP-1 Peptide Atlas, by Delfa

CompletedPhase 2

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Lead sponsor

Eli Lilly and Company

Asset

Eloralintide

Subcutaneous · Amylin analog

Listed sites

Recruiting sites

—

Enrollment

263

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥27

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06230523

Org study ID18808

Secondary IDW8M-MC-LAA1Intervention-specific appendix (ISA) number

Timeline

Milestones

Study first posted2024-01-30actual

Study start2024-02-05actual

Primary completion2025-05-30actual

Study completion2025-08-14actual

Last update posted2025-08-28actual

Assets

Investigational agents

Eloralintide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

W8M-MC-LAA1

•Are males and females who agree to abide by the reproductive and contraceptive requirements

W8M-MC-CWMM:

•Have a BMI ≥27 kg/m²

•Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)

Exclusion criteria

W8M-MC-LAA1

•Have any prior diagnosis of diabetes mellitus except gestational diabetes.

•Have any of the following cardiovascular conditions within 6 months prior to screening:

–acute myocardial infarction

–cerebrovascular accident (stroke)

–unstable angina, or

–hospitalization due to congestive heart failure (CHF).

•Have a history of acute or chronic pancreatitis.

•Have an on-going or history of bradyarrhythmia and/or sinus bradycardia at screening and baseline.

W8M-MC-CWMM

•Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.

•Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.

•Have poorly controlled hypertension.

•Have a history of symptomatic gallbladder disease within the past 2 years

•Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.

•Have a lifetime history of suicide attempts.

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Safety / tolerability / PK

Weight & body composition

5 endpoints

Primary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 48

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Body Weight

Time frame:Baseline, Week 48

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥5% Body Weight Reduction

Time frame:Baseline to Week 48

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥10% Body Weight Reduction

Time frame:Baseline to Week 48

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change from Baseline in Body Mass Index (BMI)

Time frame:Baseline, Week 48

BMI, change

change from baseline, improvement

Safety / tolerability / PK

2 endpoints

Secondary/protocol endpoint

Pharmacokinetics (PK): Area Under the Curve (AUC) of LY3841136

Time frame:Baseline to Week 48

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

PK: Maximum Concentration (Cmax) of LY3841136

Time frame:Baseline to Week 48

Cmax

concentration, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
Lancet (London, England)2025 Dec 6PMID41207310doi:10.1016/S0140-6736(25)02155-5via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.